Fecal Calprotectin in assessing Familial Mediterranean Fever Patients | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Afro-Egyptian Journal of Infectious and Endemic Diseases | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Article 9, Volume 13, Issue 3, September 2023, Page 206-211 PDF (350.73 K) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Document Type: Original Article | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DOI: 10.21608/aeji.2023.225900.1306 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 View on SCiNiTO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Authors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aya M Mahros  ; Eslam El Shenawy; Mohammed Hussien Ahmed
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Department of Hepatology, Gastroenterology and Infectious Disease, Faculty of Medicine, Kafrelsheikh University, Kafr Elshikh, Egypt. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Background and study aims: Familial Mediterranean fever (FMF) is an autoinflammatory disease presented by inflammatory attacks. Calprotectin (FC) is a calcium-binding protein that is found mainly in neutrophils, in monocytes and reactive macrophages. It considered a cytokine released from monocytes and neutrophils as a result of tissue trauma and inflammation. This study aimed to investigate fecal calprotectin levels in FMF patients as predictor of disease activity. Patients/Material and Methods: This is a Prospective cross-sectional study. Between May 2020 and May 2022, 158 patients diagnosed with FMF in our outpatient clinic in Kafrelsheikh university hospital after confirmation by PCR and obtaining Medical consent for participation in this study. Blood was collected from a peripheral vein to complete blood picture, ESR, CRP, Amyloid A, Faecal calprotectin. Blood tests were examined by ELISA; the study protocol was approved by the local ethics committee. Results: We enrolled 158 patients among them 102 patients were females, and 56 were males. Largest number of patients was diagnosed at age of twenties. Attacks last in 116 patients for less than 48 hours, while lasting for more than that in 42 patients. 130 patients had heterozygous mutation(Group 1), 28 patients had homozygous mutations(Group 2) confirmed by PCR . There was a statistically significant difference between the two groups in Fecal calprotectin level at time of diagnosis (P < 0.001616). The level Calprotectin at time of diagnosis of 100 pg/mL had 96.40% sensitivity and 96.60% Specificity. Homozygous mutation had positive correlation with Colchicine dose needed to give response. Calprotectin level have negative correlation with Colchicine dose needed. Conclusion: Our finding suggests that fecal calprotectin can be used to assess the diagnosis and severity of FMF patients. However, future studies are recommended . | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Highlights | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Keywords | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| FMF; Calprotectin; inflammation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Supplementary Files
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Text | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INTRODUCTION Familial Mediterranean fever (FMF) is autoinflammatory disease presented by repeated episodes of fever and serositis [1, 2]. The etiology of FMF is not properly recognized but, mutation of the Mediterranean fever gene that is responsible for encoding a pyrin protein. As a result abnormal pyrin leads to marked inflammation leading to clinical manifestation of disease. Homozygus mutation are more liable to severe symptoms and complication [3, 4]. Four Types of gastrointestinal affection may be found in FMF patients. The first one is associated with the attack, while the second not related to the attack such as FMF. The third GIT affection is related to treatment side effects as diarrhea while the last one is malabsorption and inflammatory bowel disease [5]. Fecal calprotectin is a simple tool for assessment of the intestinal inflammation and its level are correlated with severity of intestinal inflammation [6,7]. Many conditions are associated with increase the level of fecal calprotectin such as IBD and (NSAID) use.[8, 9] Many recent studies suggest that FC may be more accurate biomarker of rheumatic diseases than ESR and CRP [10]. Previous studies in FMF patients found high fecal CLP. Subclinical inflammation may be present in FMF patients. Unfortunately there are no diagnostic markers [11]. Many inflammatory diseases are prevalent in FMF patients as amyloidosis, Vasculitis and inflammatory bowel disease [12]. Colonoscopy is the gold standard to evaluate gut mucosal inflammation, However it is a expensive, difficult in children and invasive procedure [13]. So there is a need for a simple non invasive methods for evaluation of mucosal inflammation. This study aimed to evaluate fecal calprotectin levels in FMF patients as predictor of disease activity. PATIENTS AND METHODS We included patients diagnosed with FMF according to the Yalçınkaya criteria 13 in our outpatient clinic at Kafrelsheikh University Hospital between May 2020 and May 2022. Patients subjected to history taking, clinical and laboratory evaluation (CBC, CRP, ESR, albumin and Fecal calprotectin). We excluded patients with other causes of raised FC such as those who took NSAID. The stool samples were stored at temperature less than 8°C until assay. And we avoided alternating freezing and thawing of the samples. FC ≤50 μg/g was defined as normal, and >50 μg/g as abnormal. Other major causes of raised FC as drugs, infection, inflammatory bowel disease, and amyloidosis were excluded from our study by stool analysis, and by doing endoscopy and colonoscopy followed by histopathology RESULTS We included 158 patients. Among them 102 patients were females, and 56 were males. We included 142 patients from Baltium, 12 from Kalian and 4 from Bela. Largest number of patients was diagnosed at age of twenties. Only 5 patients were diagnosed at fifties. 72 patients had more than 6 attacks, 65 patients had 3 to 6 attacks and 21 patients had less than 3 attacks per year. Attacks last in 116 patients for less than 48 hours, while lasting for more than that in 42 patients. Ninety six patients had negative parent consanguinity. 30 patients had history of abdominal surgery. We reported that 130 patients had heterozygous mutation and 28 patients had homozygous mutations confirmed by PCR (Figure 1). Laboratory evaluation of our patients revealed that WBC and platelet count showed significant difference between Homozygous and Heterozygous groups (P value = 0.000) while ESR, CRP, and Amyloid A levels showed insignificant difference between the two groups Table (1). Our study reported that FC levels were raised at time of diagnosis above the normal range in both homozygous and heterozygous patients(n Table (2) ROC analysis of Calprotectin level at time of diagnosis showed significant difference from ESR, CRP and Amyloid A levels with calprotectin value of 100 pg/mL had 96.40% sensitivity and 96.60% Specificity. Table (4) and Figure 2 Statistical analysis Statistical assessments were performed using SPSS 22 software. We calculate the mean and median for the data with normal and abnormal distribution. For quantitative data, Mann-Whitney and T-tests were used. A chi-square test was used to compare the categorical data. Spearman test was used to find out correlation between quantitative variables. The area under the ROC curve were calculated with a 95% confidence interval (CI). The sensitivity, specificity, positive predictive value, and negative predictive value for optimum cut-off values were in the 95% CI. The significance level was P < 0.05. Table (1): Showed lab finding in each group.
WBCs: white blood cells, RBCs: red blood cells, Hb: hemoglobin, MCV: mean corpuscular volume. ESR: erythrocyte sedimentation rate, CRP: c reactive protein. Table (2): Showed calprotectin level and dose of Colachicine needed to give response.
Table (3): ROC analysis values.
ESR: erythrocyte sedimentation rate, CRP: C reactive protein DISCUSSION Familial Mediterranean fever (FMF) is autoinflammatory disease presented by repeated episodes of fever and serositis. Several markers as CRP, ESR, Amyloid, WBC used to detect systemic inflammation in FMF [14]. However these markers of low sensitivity and specificity for the diagnosis of subclinical intestinal inflammation. Fc is a marker used to detect inflammation from activated lymphocyte and neutrophiles in intestinal mucosa [15]. However, there are other etiologies to raise its level [16-18]. To exclude other cause of raised FC, we excluded patients with any chronic disease, those known to have IBD or other intestinal pathology on colonoscopy, those who were using NSAIDs and confirmed that all fecal samples were normal at the time of raised FC. Many studies addressed the role of FC in rheumatic diseases like rheumatoid arthritis, scleroderma and Sjögren's syndrome [19,20]. As patients with homozygous mutation have more sever disease than those with heterozygote mutation, our study revealed increase platelet count in homozygotes than heterozygote, Similarly, a previous study revealed increased platelet activation in FMF patients [21]. In the current study, the FC level in the FMF patient was higher than normal (>50 μg/g) in both FMF groups and the level were significantly higher in homozygous than heterozygous group. This is in line with a study by Gucenmezet al. found that Fecal calprotectin level in FMF patients was significantly higher than in healthy patients [10]. So we suggest that FC can be used for diagnosis and follow up of FMF patients. High level of FMF may be due to chronic inflammation in FMF patients. Another study by Fatma et al concluded that FC is noninvasive simple method for assessing inflammation in childern with FMF patients [22]. The Study limitations were a relatively low number of patients and that it was cross-sectional. CONCLUSION Our finding suggests that fecal calprotectin can be used to assess the diagnosis and severity of FMF patients. However, future studies are recommended. Abbreviations: FC: Fecal calprotectin, ESR: Erythrocyte sedimentation rate, FMF: Familial Mediterranean fever Conflict of interest: None Funding: No Ethical considerations: The study was approved by the Ethics Committee of Kafrelsheikh University . Written informed consent was obtained from the patient. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| References | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
1-Ahmed, M.H., Ibrahim, A.M., Ragab, S.M, Mahros, M.A. Musculoskeletal and neurological manifestations in a cohort of Egyptian Familial Mediterranean fever patients: genotype-phenotype correlation. Egypt Rheumatol Rehabil, 2022; 49, 6.
2-Gedalia A. Hereditary periodic fever syndromes. In: E Behrman, R Kleigman, eds. Nelson Textbook of Pediatrics. philadelphia, PA: WB Saunders Company; 2008: 1030.
3-Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R, Kastner DL. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore). 1998 Jul; 77(4):268-97..
4-Kastner DL. Familial Mediterranean fever: the genetics of inflammation. Hosp Prac. 1998; 33: 131- 146.
5-Beser OF, Kasapcopur O, Cokugras FC, Kutlu T, Arsoy N, Erkan T. Association of inflammatory bowel disease with familial Mediterranean fever in Turkish children. J Pediatr Gastroenterol Nutr. 2013; 56: 498- 502.
6-Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50- 54.
7-Ahmed M, Emara M, Saeed E, Abouelfetouh M, Mahros A. 'How Valuable are Noninvasive Tests as Indicators of IBD Activity and Severity in the Primary Health Care ', Afro-Egyptian Journal of Infectious and Endemic Diseases 2021; 11(2), pp. 113-119.
8-Gisbert JP, Mcnicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009; 41: 56- 66.
9-Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999 Sep;45(3):362-6.
10-Gucenmez OA, Kume T, Makay B, Babayigit O, Arslan N, Unsal E. Role of fecal calprotectin in the assessment of intestinal inflammation in children with familial Mediterranean fever. Int J Rheum Dis. 2018;21(10):1844–1848.
11-Mor A, Gal R, Livneh A. Abdominal and digestive system associations of familial Mediterranean fever. Am. J. Gastroenterol. 2003; 98: 2594– 604.
12-Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: Indications, surveillance, and use in clinical practice. Clin. Gastroenterol. Hepatol. 2005; 3: 11– 24.
13-Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4):395-8.
14-Ahmed MH, El Henawy O, ElShennawy EM, Mahros AM. Clinical and genetic characterization of familial Mediterranean fever among a cohort of Egyptian patients. Prz Gastroenterol. 2022;17(3):240-244.
15-Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008 Jul;40(7):547-53..
16-Fallahi G, Motamed F, Yousefi A, Shafieyoun A, Najafi M, Khodadad A, et al. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr. 2013 Sep-Oct;55(5):475-8..
17-Ashorn S, Honkanen T, Kolho KL, Ashorn M, Välineva T, Wei B, et al. Fecal calprotectin levels and serological responses to microbial agents among children and adolescents with inflammatory bowel disease. Inflamm. Bowel Dis.2009;15: 199–205.
18-Canani RB, de Horatio LT, Terrin G, Romano MT, Miele E, Staiano A, Rapacciuolo L, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach toa child with suspected inflammatory bowel disease.J. Pediatr.Gastroenterol. Nutr.2006;42:9–15.
19-Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken) 2016;68(7):899–906.
20-Mads Abildtrup, Gabrielle H. Kingsley and David L. Scott, Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42(5):760–770.
21-Coban E, Adanir H. Platelet activation in patients with Familial Mediterranean Fever. Platelets. 2008 Sep;19(6):405-8.
22-Demirbaş F, Çaltepe G, Comba A, Abbasguliyev H, Uyar NY, Kalaycı AG. Fecal calprotectin in children with familial Mediterranean fever in the attack-free period. Pediatr Int. 2019 Nov;61(11):1140-1145. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Statistics Article View: 950 PDF Download: 448 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
